Swedish biotech crum­bles in face of PhII fail­ure of prostate can­cer vac­cine

Swedish biotech Rho­Vac saw its shares plum­met by 90% Mon­day af­ter its lead can­cer vac­cine can­di­date failed a Phase II study.

In ap­prox­i­mate­ly 180 pa­tients, the treat­ment did not stop pro­gres­sion of prostate can­cer com­pared to place­bo in pa­tients who showed signs of can­cer re­cur­rence. The biotech did not sug­ar­coat the news, say­ing in its press re­lease that “the pri­ma­ry out­come analy­sis ob­vi­ous­ly of­fers lit­tle hope of a li­cense or ac­qui­si­tion deal based on the re­sults of this study alone.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER